OrthoPediatrics Announces FDA 510(k) Clearance for its 25th Surgical System, Pediatric Nailing Platform

OrthoPediatrics (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce U.S. Food and Drug Administration (FDA) 510k clearance for the Pediatric Nailing Platform | FEMUR, the Company’s 25^th surgical system.

As quoted in the press release:

The new system utilizes high precision, innovative, and best-in-class instruments to accompany two distinct pediatric-specific nail offerings. The platform is an unparalleled upgrade to the legacy system and the next step in the evolution of the Company’s Intramedullary Nailing franchise.

Luis Vega, MD, OrthoPediatrics’ Engineering Director of Trauma and Deformity Correction, stated, “Our team is excited about the Pediatric Nailing Platform. We worked alongside pediatric orthopedic surgeons to create a system which features dedicated child and adolescent offerings, enhanced fixation options, and state-of-the-art instrumentation. The new platform will allow surgeons to treat a wider range of children and pathologies and serve as the foundation for future intramedullary nailing endeavors.”

Click here to read the full press release.